Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model
- PMID: 9406711
- DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2567::aid-cncr32>3.3.co;2-4
Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model
Abstract
Background: Improved understanding of dose and effective dose calculations may contribute to the optimization of fractionated radioimmunotherapy.
Methods: Comparison three-dimensional tumor dosimetry was performed on athymic nude mice bearing established LS174T human colon carcinoma xenografts. Mice were given bolus intraperitoneal injections of 300 microCi 131I-labeled CC49 monoclonal antibody once (Day 0) or three times (Days 0, 3, and 7) or continuous intraperitoneal infusion with miniosmotic pumps over 7 days. Serial section autoradiography was used to reconstruct tumor activity density distributions for Days 3, 4, 7, 10, and 11 (single injection); Days 3, 4, 7, 8, and 11 (3 injections); and Days 4, 7, 10, and 13 (pump). At least three tumors were reconstructed at each time point. Uptakes in blood and tumor were measured up to 14 days (single injection), 11 days (3 injections), or 16 days (pump) after injection.
Results: Average dose values calculated from total activity uptake data only (assuming no energy loss external to the tumor) yielded 102 Gy (single injection), 158 Gy (three injections), and 47 Gy (pump). Average doses using three-dimensional dose calculations were 88 Gy, 139 Gy, and 40 Gy, respectively. The nonuniformity of dose deposition affects treatment outcome, because cell loss is an exponential function of dose. Using the linear quadratic model with fractional cell survival to define an effective dose, D(eff) were calculated to be 20 Gy, 23 Gy, and 14 Gy, respectively. Cell proliferation affects outcome for variable dose-rate treatments. With cell proliferation parameters set to reproduce single-fraction 60Co recurrence results, D(eff) (for local control endpoint) were 8.9 Gy, 12.8 Gy, and 3.9 Gy, respectively. Three bolus injections compared with a single bolus injection were relatively less efficient in tumor uptake. However, three bolus injections resulted in a more uniform dose rate over a longer period, resulting in a 50% improvement in D(eff). The slower dose delivery for pump infusion resulted in a significantly lower D(eff), although dose-rate distributions were more uniform compared with the single bolus injection.
Conclusions: Improvement in dose-rate nonuniformities was observed for fractionated and continuous radiolabeled monoclonal antibody injections. Fractionated injections produced superior dosimetric results compared with single bolus or continuous injections.
Similar articles
-
Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.Clin Cancer Res. 1999 Oct;5(10 Suppl):3153s-3159s. Clin Cancer Res. 1999. PMID: 10541357
-
Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.Cancer Res. 1995 Dec 1;55(23 Suppl):5881s-5887s. Cancer Res. 1995. PMID: 7493364
-
A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography.Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):165-72. doi: 10.1016/s0360-3016(96)85026-7. Int J Radiat Oncol Biol Phys. 1996. PMID: 8641915
-
Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors.Curr Opin Immunol. 1991 Oct;3(5):685-93. doi: 10.1016/0952-7915(91)90097-k. Curr Opin Immunol. 1991. PMID: 1755986 Review.
-
Malignant ascites: review of the literature, and an update on monoclonal antibody-targeted therapy.Eur J Obstet Gynecol Reprod Biol. 1989 Jul;32(1):37-45. doi: 10.1016/0028-2243(89)90125-1. Eur J Obstet Gynecol Reprod Biol. 1989. PMID: 2670627 Review.
Cited by
-
Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice.Br J Cancer. 2008 Aug 19;99(4):632-8. doi: 10.1038/sj.bjc.6604511. Br J Cancer. 2008. PMID: 18682714 Free PMC article.
-
Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.J Nucl Med. 2010 Apr;51(4):654-9. doi: 10.2967/jnumed.109.067298. Epub 2010 Mar 17. J Nucl Med. 2010. PMID: 20237032 Free PMC article. Clinical Trial.
-
Antibody therapy of non-Hodgkin's B-cell lymphoma.Cancer Immunol Immunother. 2003 May;52(5):257-80. doi: 10.1007/s00262-002-0347-6. Epub 2003 Feb 28. Cancer Immunol Immunother. 2003. PMID: 12700943 Free PMC article. Review.
-
Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy.Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):981-5. doi: 10.1007/s00259-004-1497-x. Epub 2004 Feb 28. Eur J Nucl Med Mol Imaging. 2004. PMID: 14991242
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources